NeuroSense Therapeutics (NRSN)
Develops PrimeC, a fixed-dose combination therapy for ALS.
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada. CAMBRIDGE, Mass.
NeuroSense Issues CEO Letter to Shareholders
CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PR Newswire
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallma
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression PrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapy CAMBRIDGE, Mass., June 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings support continued development of PrimeC's multi-target approach in Alzheimer's disease CAMBRIDGE, Mass., June 25, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC CAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantage Results published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activity Advancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readout CAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell?
Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) traded down 14.7% during trading on Wednesday. The stock traded as low as $0.8531 and last traded at $0.8531. 931,449 shares were traded during trading, an increase of 337% from the average session volume of 213,025 shares. The stock had previously closed at $1.00.